Related Experiment Videos
HDL cholesterol and beta-adrenoceptor blocking agents in a 5 year multifactorial primary prevention trial
Insights
Beta-blockers like pindolol may slightly lower high-density lipoprotein (HDL) cholesterol, potentially impacting heart disease risk. Further research is needed to clarify the clinical significance of these findings in primary prevention.
Area of Science:
- Cardiology
- Pharmacology
- Preventive Medicine
Background:
- Primary prevention trials aim to reduce ischemic heart disease incidence.
- Serum high-density lipoprotein (HDL) cholesterol is a key cardiovascular risk factor.
- Drug therapies, including beta-blockers, can influence lipid profiles.
Purpose of the Study:
- To evaluate the effect of beta-adrenoceptor blocking agents on serum HDL cholesterol levels.
- To investigate the impact of combination therapies on HDL cholesterol.
- To assess the influence of drug withdrawal on HDL cholesterol.
Main Methods:
- Analysis of serum HDL cholesterol in a 5-year multifactorial primary prevention trial.
- Subgroup analysis of patients treated with beta-blockers (pindolol) alone or with diuretics.
- Comparison of HDL cholesterol levels between different treatment groups and a control group.
- Assessment of HDL cholesterol changes after drug withdrawal.
Main Results:
- Drug-treated subjects exhibited notably low HDL cholesterol levels.
- Beta-blockers, particularly pindolol, showed inconsistent effects on HDL cholesterol.
- Combined beta-blocker and hypolipidaemic treatment resulted in lower HDL cholesterol than hypolipidaemic agents alone.
- Pindolol withdrawal led to a modest but significant HDL cholesterol increase in some patients.
Conclusions:
- Pindolol may slightly reduce serum HDL cholesterol.
- The clinical relevance of this minor reduction in HDL cholesterol for ischemic heart disease incidence is uncertain.
- Further investigation is warranted to understand the cardiovascular implications of beta-blocker-induced changes in HDL cholesterol.
Abstract:
1 Serum HDL cholesterol measured at the end of a 5 year multifactorial primary prevention trial, aimed to reduce risk factor levels and incidence of ischaemic heart disease, revealed quite low values in drug-treated subjects. 2 Analysis of subgroups treated with beta-adrenoceptor blocking agents (mainly pindolol) alone or in different combinations with diuretics showed inconsistent effects of beta-adrenoceptors blockers on serum HDL cholesterol. HDL cholesterol levels in patients treated with pindolol with or without a diuretic were not different from those of the risk-free control group. 3 Subjects on combined beta-adrenoceptor blocker-hypolipidaemic treatments had lower HDL-cholesterol than those on hypolipidaemic agents alone. 4 Withdrawal of pindolol at the end of the trial caused a small but significant increase in serum HDL cholesterol in a small subgroup of mildly hypertensive patients. Thus, pindolol appears to have slightly reduced serum HDL cholesterol but the relevance of this small decrease on the incidence of ischaemic heart disease is questionable.